featured
Donafenib for Progressive, Radioactive Iodine–Refractory, Differentiated Thyroid Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer
Clin. Cancer Res 2023 May 15;[EPub Ahead of Print], Y Lin, S Qin, H Yang, F Shi, A Yang, X Han, B Liu, Z Li, Q Ji, L Tang, Z Deng, Y Ding, W Fu, X Xie, L Li, X He, Z Lv, Q Ma, Z Shen, Z Guo, Z Chen, Y Cui, J Tan, Z Gao, S Jing, K Lu, X Luo, Y Zhang, Y Fang, Z Li, Y Cheng, S Lei, S Luan, G Chen, G Wang, L Wu, L LiuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.